Entering text into the input field will update the search result below

Flexion down 2% premarket on extension of FDA action date for repeat injections of Zilretta

Oct. 14, 2019 7:38 AM ETPacira BioSciences, Inc. (PCRX) StockPCRXBy: Douglas W. House, SA News Editor1 Comment
  • Flexion Therapeutics (NASDAQ:FLXN) slips 2% premarket on light volume in response to an extension of the FDA's action date for its review of its application seeking approval for repeat injections of Zilretta (triamcinolone acetonide extended-release injectable suspension) in patients with knee pain due to osteoarthritis. The PDUFA date was today.
  • The agency has not identified a specific revised action date, but informed the company that its review should be completed in the coming weeks.
  • Zilretta was first approved in the U.S. in October 2017 (single intra-articular injection).

Recommended For You

About PCRX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
PCRX--
Pacira BioSciences, Inc.